From the Guest EditorIntroduction by the Guest EditorsGoldberg, Sarah B. MD; Herbst, Roy S. MD, PhDAuthor Information From the Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT. Conflicts of Interest and Source of Funding: S.B.G. is a consultant to AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Genentech, Spectrum, Amgen, Blueprint Medicine, Sanofi-Genzyme, and Daiichi Sankyo, and receives research funding from AstraZeneca and Boehringer-Ingelheim. R.S.H. is a consultant to Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen, and WindMIL Therapeutics; receives research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company; and is a board member (nonexecutive/independent) at Junshi Pharmaceuticals. Reprints: Sarah B. Goldberg, MD, Yale School of Medicine, 333 Cedar St, FMP-130, New Haven, CT 06510. E-mail: [email protected]. The Cancer Journal: 11/12 2020 - Volume 26 - Issue 6 - p 471-472 doi: 10.1097/PPO.0000000000000487 Buy Metrics Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.